OPRX stock icon

OptimizeRx
OPRX

$7.54
3.46%

Market Cap: $138M

 

About: OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

Employees: 136

0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

222% more call options, than puts

Call options by funds: $1.76M | Put options by funds: $548K

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

0.83% more ownership

Funds ownership: 70.77% [Q1] → 71.6% (+0.83%) [Q2]

4% less funds holding

Funds holding: 96 [Q1] → 92 (-4) [Q2]

16% less capital invested

Capital invested by funds: $156M [Q1] → $131M (-$25.3M) [Q2]

18% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 22

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$11
46%
upside
Avg. target
$14.25
89%
upside
High target
$16
112%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
RBC Capital
Sean Dodge
55% 1-year accuracy
24 / 44 met price target
86%upside
$14
Outperform
Maintained
16 Aug 2024
Barclays
Stephanie Davis
89% 1-year accuracy
8 / 9 met price target
46%upside
$11
Equal-Weight
Maintained
12 Aug 2024
JMP Securities
Constantine Davides
32% 1-year accuracy
7 / 22 met price target
112%upside
$16
Market Outperform
Reiterated
24 Jun 2024
JMP Securities
Constantine Davides
32% 1-year accuracy
7 / 22 met price target
112%upside
$16
Market Outperform
Reiterated
21 Jun 2024

Financial journalist opinion